Cited by 8,943Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke Management

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Apixaban versus Warfarin in Patients with Atrial Fibrillation

Open access

Granger, Christopher B., Alexander, John H., McMurray, John J.V., Lopes, Renato D., Hylek, Elaine M., Hanna, Michael, Al-Khalidi, Hussein R., Ansell, Jack, Atar, Dan, Avezum, Alvaro, Bahit, M. Cecilia, Diaz, Rafael, Easton, J. Donald, Ezekowitz, Justin A., Flaker, Greg, Garcia, David, Geraldes, Margarida, Gersh, Bernard J., Golitsyn, Sergey, Goto, Shinya, Hermosillo, Antonio G., Hohnloser, Stefan H., Horowitz, John, Mohan, Puneet, Jansky, Petr, Lewis, Basil S., Lopez-Sendon, Jose Luis, Pais, Prem, Parkhomenko, Alexander, Verheugt, Freek W.A., Zhu, Jun, Wallentin, Lars·2011·New England Journal of Medicine

DOI 10.1056/nejmoa1107039

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin. METHODS: In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. The primary outcome was ischemic or hemorrhagic stroke or systemic embolism. The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause. RESULTS: The median duration of follow-up was 1.8 years. The rate of the primary outcome was 1.27% per year in the apixaban group, as compared with 1.60% per year in the warfarin group (hazard ratio with apixaban, 0.79; 95% confidence interval [CI], 0.66 to 0.95; P<0.001 for noninferiority; P=0.01 for superiority). The rate of major bleeding was 2.13% per year in the apixaban group, as compared with 3.09% per year in the warfarin group (hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P<0.001), and the rates of death from any cause were 3.52% and 3.94%, respectively (hazard ratio, 0.89; 95% CI, 0.80 to 0.99; P=0.047). The rate of hemorrhagic stroke was 0.24% per year in the apixaban group, as compared with 0.47% per year in the warfarin group (hazard ratio, 0.51; 95% CI, 0.35 to 0.75; P<0.001), and the rate of ischemic or uncertain type of stroke was 0.97% per year in the apixaban group and 1.05% per year in the warfarin group (hazard ratio, 0.92; 95% CI, 0.74 to 1.13; P=0.42). CONCLUSIONS: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. (Funded by Bristol-Myers Squibb and Pfizer; ARISTOTLE ClinicalTrials.gov number, NCT00412984.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1107039

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
Schulman, S., & Kearon, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,025
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,070
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
(2006) · The Lancet · doi:10.1016/s0140-6736(06)68845-4 · Cited by 1,952
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation
Hart, R. G., Benavente, O., McBride, R., & Pearce, L. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-7-199910050-00003 · Cited by 1,636
Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation: An Analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) Trial
Eikelboom, J. W., Wallentin, L., Connolly, S. J., Ezekowitz, M., Healey, J. S., Oldgren, J., Yang, S., Alings, M., Kaatz, S., Hohnloser, S. H., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.004747 · Cited by 1,081
Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
Alexander, J. H., Lópes, R. D., James, S. K., Kilaru, R., He, Y., Mohan, P., Bhatt, D. L., Goodman, S. G., Verheugt, F. W. A., Flather, M. D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105819 · Cited by 1,002
Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans
Raghavan, N., Frost, C. E., Yu, Z., He, K., Zhang, H., Humphreys, W. G., Pinto, D. J. P., Chen, S.-Y., Bonacorsi, S. J., Wong, P. C., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023143 · Cited by 610

Flagged first, then by citations

Show all 15 references

Sorted by citations

Items 601–700 of 1,013

Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients
Capodanno, D., Capranzano, P., Giacchi, G., Calvi, V. I., & Tamburino, C. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.148 · Cited by 98
Bleeding and antidotes in new oral anticoagulants
Majeed, A., & Schulman, S. (2013) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2013.07.001 · Cited by 99
Self-reported adherence to anticoagulation and its determinants using the Morisky medication adherence scale
Castellucci, L. A., Shaw, J. R., van der Salm, K., Erkens, P. M. G., Gal, G. L., Petrcich, W., & Carrier, M. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.007 · Cited by 100
Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF
Reddy, V. Y., Akehurst, R. L., Armstrong, S. O., Amorosi, S. L., Beard, S. M., & Holmes, D. R. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.09.084 · Cited by 99
The evolution of anticoagulant therapy.
Franchini, M., Liumbruno, G. M., Bonfanti, C., & Lippi, G. (2016) · PubMed · doi:10.2450/2015.0096-15 · Cited by 102
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine
Alexander, J. H., Andersson, U., Lópes, R. D., Hijazi, Z., Hohnloser, S. H., Ezekowitz, J. A., Halvorsen, S., Hanna, M., Commerford, P., Rużyłło, W., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1829 · Cited by 99
Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis
Caron, F., Leong, D. P., Hillis, C., Fraser, G. A. M., & Siegal, D. M. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016001883 · Cited by 100
Evaluation of bleeding in patients receiving direct oral anticoagulants
Hellenbart, E. L., Faulkenberg, K. D., & Finks, S. W. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s121661 · Cited by 100
Sex Differences in Atrial Fibrillation
Andrade, J. G., Deyell, M. W., Lee, A. K. Y., & Macle, L. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.11.022 · Cited by 100
Meta-Analysis of Direct-Acting Oral Anticoagulants Compared With Warfarin in Patients >75 Years of Age
Malik, A. H., Yandrapalli, S., Aronow, W. S., Panza, J. A., & Cooper, H. A. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.02.060 · Cited by 102
Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis
Gu, Z., Wei, A., Zhang, C., Wang, X., Zhang, L., Shen, L., Li, Z., Pan, M.-M., Liu, X.-Y., Pu, J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.056 · Cited by 102
2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D. A., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A. M., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.02.009 · Cited by 111
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Bounameaux, H., & Camm, A. J. (2014) · Drugs · doi:10.1007/s40265-014-0261-1 · Cited by 97
How to Use a Noninferiority Trial
Mulla, S. M., Scott, I. A., Jackevicius, C. A., You, J. J., & Guyatt, G. H. (2012) · JAMA · doi:10.1001/2012.jama.11235 · Cited by 97
Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis
Martin, A., Bonniec, B. L., Fischer, A., Marchand‐Leroux, C., Gaussem, P., Samama, C. M., & Godiér, A. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.152 · Cited by 96
Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices?
Alamneh, E. A., Chalmers, L., & Bereznicki, L. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0161-8 · Cited by 98
The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale
Douketis, J. D., Spyropoulos, A. C., Anderson, J., Arnold, D. M., Bates, S. M., Blostein, M. D., Carrier, M., Caprini, J. A., Clark, N. P., Coppens, M., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-08-0553 · Cited by 99
Percutaneous Left Atrial Appendage Occlusion for Stroke Prophylaxis in Nonvalvular Atrial Fibrillation
Bajaj, N. S., Parashar, A., Agarwal, S., Sodhi, N., Poddar, K. L., Garg, A., Tuzcu, E. M., & Kapadia, S. R. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2013.11.010 · Cited by 97
Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban
Frost, C. E., Song, Y. J., Shenker, A., Wang, J. J. J., Barrett, Y. C., Schuster, A. E., Harris, S. I., & LaCreta, F. P. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0228-0 · Cited by 95
Ablation for Atrial Fibrillation in Combination With Left Atrial Appendage Closure: First Results of a Feasibility Study
Swaans, M. J., Post, M. C., Rensing, B. J. W. M., & Boersma, L. V. A. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.002212 · Cited by 95
Off-label dosing of non–vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation
Chan, Y., Chao, T., Chen, S., Lee, H., Yeh, Y., Huang, Y.-C., Chang, S., Kuo, C.-T., Lip, G. Y. H., & Chen, S. (2020) · Heart Rhythm · doi:10.1016/j.hrthm.2020.07.022 · Cited by 97
Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries
Wheelock, K. M., Ross, J. S., Murugiah, K., Lin, Z., Krumholz, H. M., & Khera, R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.37288 · Cited by 98
Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation
Landmesser, U., Skurk, C., Kirchhof, P. F., Lewalter, T., Hartung, J. J., Rroku, A., Pieske, B. M., Brachmann, J., Akın, İ., Jacobshagen, C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2513310 · Cited by 106
A New Era for Anticoagulation in Atrial Fibrillation
Mega, J. L. (2011) · New England Journal of Medicine · doi:10.1056/nejme1109748 · Cited by 96
Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin: The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial
Flaker, G. C., Eikelboom, J. W., Shestakovska, O., Connolly, S. J., Kaatz, S., Budaj, A., Husted, S., Yusuf, S., Lip, G. Y. H., & Hart, R. G. (2012) · Stroke · doi:10.1161/strokeaha.112.664144 · Cited by 94
Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: A systematic review and meta-analysis
Yang, J., Chen, Y., Li, X., Wei, X., Chen, X., Zhang, L., Zhang, Y., Xu, Q., Wang, H., Li, Y., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.151 · Cited by 94
Cerebral Microbleeds on Magnetic Resonance Imaging and Anticoagulant-Associated Intracerebral Hemorrhage Risk
Charidimou, A., Shakeshaft, C., & Werring, D. J. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00133 · Cited by 98
Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
Hoffman, M., & Dickneite, G. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-05-0431 · Cited by 95
Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab
Asirvatham, S. J., Hu, T. Y., & Vaidya, V. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s89130 · Cited by 95
Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation
Hijazi, Z., Aulin, J., Andersson, U., Alexander, J. H., Gersh, B. J., Granger, C. B., Hanna, M., Horowitz, J. D., Hylek, E. M., Lópes, R. D., et al. (2016) · Heart · doi:10.1136/heartjnl-2015-308887 · Cited by 94
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary
Steffel, J., Verhamme, P. B., Potpara, T., Albaladejo, P., Antz, M., Desteghe, L., Hæusler, K. G., Oldgren, J., Reinecke, H., Roldán, V., et al. (2018) · Kardiologia Polska · doi:10.5603/kp.2018.0180 · Cited by 93
Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
Lee, H., Chan, Y., Chang, S., Tu, H., Chen, S., Yeh, Y., Wu, L., Kuo, C., Kuo, C.-T., & See, L. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011112 · Cited by 94
Invited review: hypertension and atrial fibrillation: epidemiology, pathophysiology, and implications for management
Gumprecht, J. J., Domek, M., Lip, G. Y. H., & Shantsila, A. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-019-0279-7 · Cited by 98
Secondary stroke prevention in people with atrial fibrillation: treatments and trials
Seiffge, D. J., Cancelloni, V., Räber, L., Paciaroni, M., Metzner, A., Kirchhof, P. F., Fischer, U., Werring, D. J., Shoamanesh, A., & Caso, V. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00037-1 · Cited by 101
Advantages and limitations of the new anticoagulants
Schulman, S. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12138 · Cited by 98
Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial
Mahaffey, K. W., Stevens, S. R., White, H. D., Nessel, C. C., Goodman, S. G., Piccini, J. P., Patel, M. R., Becker, R. C., Halperin, J. L., Hacke, W., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht428 · Cited by 92
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight
Lee, S., Choi, E., Park, C. S., Han, K., Jung, J., Oh, S., & Lip, G. Y. H. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.051 · Cited by 92
The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis
Naymagon, L., Tremblay, D. A., Zubizarreta, N. J., Moshier, E. L., Troy, K. M., Schiano, T. D., & Mascarenhas, J. O. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001310 · Cited by 92
Decade-long Trends in Atrial Fibrillation Incidence and Survival: A Community Study
Chamberlain, A. M., Gersh, B. J., Alonso, Á., Chen, L. Y., Berardi, C., Manemann, S. M., Killian, J. M., Weston, S. A., & Roger, V. L. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.10.030 · Cited by 92
Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis
Nielsen, P. B., Lane, D. A., Rasmussen, L. H., Lip, G. Y. H., & Larsen, T. B. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0797-9 · Cited by 97
Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collection
Kermer, P., Eschenfelder, C. C., Diener, H., Grond, M., Abdalla, Y., Althaus, K., Berrouschot, J., Cangür, H., Daffertshofer, M., Edelbusch, S., et al. (2017) · International Journal of Stroke · doi:10.1177/1747493017701944 · Cited by 94
Atrial fibrillation and cancer – An unexplored field in cardiovascular oncology
Chu, G. K. T., Versteeg, H. H., Verschoor, A. J., Trines, S. A. I. P., Hemels, M. E. W., Ay, C., Huisman, M. V., & Klok, F. A. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.03.005 · Cited by 94
Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke
Xian, Y., Xu, H., O'Brien, E. C., Shah, S. D., Thomas, L. E., Pencina, M. J., Fonarow, G. C., Olson, D. M., Schwamm, L. H., Bhatt, D. L., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.2099 · Cited by 94
The bidirectional association between atrial fibrillation and myocardial infarction
Frederiksen, T. C., Dahm, C. C., Preis, S. R., Lin, H., Trinquart, L., Benjamin, E. J., & Kornej, J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00857-3 · Cited by 95
Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies
Roskell, N. S., Samuel, M., Noack, H., & Monz, B. U. (2013) · EP Europace · doi:10.1093/europace/eut001 · Cited by 91
Ischaemic and haemorrhagic stroke associated with non-vitamin K antagonist oral anticoagulants and warfarin use in patients with atrial fibrillation: a nationwide cohort study
Stærk, L., Fosbøl, E. L., Lip, G. Y. H., Lamberts, M., Bonde, A. N., Torp-Pedersen, C. T., Ozenne, B., Gerds, T. A., Gislason, G., & Olesen, J. B. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw496 · Cited by 92
Pre dicting D eterminants of A trial Fibrillation or Flutter for T herapy E lucidation in Patients at Risk for Thromboembolic Events (PREDATE AF) Study
Nasir, J. M., Pomeroy, W. C., Marler, A. T., Hann, M. C., Baykaner, T., Jones, R., Stoll, R., Hursey, K., Meadows, A., Walker, J., et al. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.04.026 · Cited by 92
Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation
Alalwan, A. A., Voils, S. A., & Hartzema, A. G. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160756 · Cited by 89
Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation
Hernandez, I., Zhang, Y., & Saba, S. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.07.092 · Cited by 91
Atrial Fibrillation in Older People: Concepts and Controversies
Zathar, Z., Karunatilleke, A., Fawzy, A. M., & Lip, G. Y. H. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00175 · Cited by 94
Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel
Baugh, C. W., Levine, M. P., Cornutt, D., Wilson, J. W., Kwun, R., Mahan, C. E., Pollack, C. V., Marcolini, E. G., Milling, T. J., Peacock, W. F., et al. (2019) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2019.09.001 · Cited by 95
Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants
Ingason, A. B., Hreinsson, J. P., Agustsson, A. S., Lund, S. H., Rumba, E., Pálsson, D. A., Reynisson, I. E., Guðmundsdóttir, B. R., Onundarson, P. T., & Bjornsson, E. S. (2021) · Annals of Internal Medicine · doi:10.7326/m21-1474 · Cited by 93
Direct‐acting oral anticoagulants: pharmacology, indications, management, and future perspectives
Gómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A. I., & Vargas, E. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12610 · Cited by 96
Stroke Prevention in Atrial Fibrillation Patients With Chronic Kidney Disease
Hart, R. G., Eikelboom, J. W., Brimble, K. S., McMurtry, M. S., & Ingram, A. J. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.04.005 · Cited by 89
Immediate and One-year Results in 35 Consecutive Patients After Closure of Left Atrial Appendage With the Amplatzer Cardiac Plug
López-Mínguez, J. R., Gragera, J. E., González-Fernández, R., Fernández-Vegas, C., Fuentes‐Cañamero, M. E., Millán-Núñez, V., Nogales‐Asensio, J. M., Martinez–Naharro, A., Sánchez-Giralt, S., Doblado-Calatrava, M., et al. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2012.04.017 · Cited by 89
Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011–2015 in Denmark
Stærk, L., Fosbøl, E. L., Gadsbøll, K., Sindet‐Pedersen, C., Pallisgaard, J. L., Lamberts, M., Lip, G. Y. H., Torp-Pedersen, C. T., Gislason, G., & Olesen, J. B. (2016) · Scientific Reports · doi:10.1038/srep31477 · Cited by 93
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Angiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J., Granger, C. B., Mauri, L., et al. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004395 · Cited by 90
Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015
Kjerpeseth, L. J., Ellekjær, H., Selmer, R. M., Ariansen, I., Furu, K., & Skovlund, E. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2296-1 · Cited by 92
Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis
Kim, J. Y., Kim, S., Myong, J., Kim, Y. R., Kim, T., Kim, J., Jang, S.-W., Oh, Y., Lee, M. Y., & Rho, T. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.12.047 · Cited by 93
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials
Deitelzweig, S., Amin, A., Jing, Y., Makenbaeva, D., Wiederkehr, D., Lin, J., & Graham, J. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.680555 · Cited by 91
DOACs – advances and limitations in real world
Lee, L. H. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0111-3 · Cited by 91
Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
Westenbrink, B. D., Alings, M., Granger, C. B., Alexander, J. H., Lópes, R. D., Hylek, E. M., Thomas, L. E., WOJDYLA, D. M., Hanna, M., Keltai, M., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.12.008 · Cited by 91
Apixaban versus Aspirin for Embolic Stroke of Undetermined Source
Geisler, T., Keller, T., Martus, P., Poli, K., Serna-Higuita, L. M., Schreieck, J., Gawaz, M., Tünnerhoff, J., Bombach, P., Nägele, T., et al. (2023) · NEJM Evidence · doi:10.1056/evidoa2300235 · Cited by 89
Atrial flutter: Clinical risk factors and adverse outcomes in the Framingham Heart Study
Rahman, F., Wang, N., Yin, X., Ellinor, P. T., Lubitz, S. A., LeLorier, P. A., McManus, D. D., SULLIVAN, L. M., Seshadri, S. S., Vasan, R. S., et al. (2015) · Heart Rhythm · doi:10.1016/j.hrthm.2015.07.031 · Cited by 90
Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients with Atrial Fibrillation
Steinberg, B. A., Greiner, M. A., Hammill, B. G., Curtis, L. H., Benjamin, E. J., Heckbert, S. R., & Piccini, J. P. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12129 · Cited by 91
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience
Eikelboom, J. W., & Merli, G. J. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.06.003 · Cited by 90
Real-world adherence and persistence with direct oral anticoagulants in adults with atrial fibrillation
Manzoor, B. S., Lee, T. A., Sharp, L. K., Walton, S. M., Galanter, W. L., & Nutescu, E. A. (2017) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1989 · Cited by 88
New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)
van Gorp, R. H., & Schurgers, L. J. (2015) · Nutrients · doi:10.3390/nu7115479 · Cited by 94
Effectiveness and Safety of Non–Vitamin K Oral Anticoagulants in Comparison to Phenprocoumon: Data from 61,000 Patients with Atrial Fibrillation
Hohnloser, S. H., Basic, E., Hohmann, C., & Näbauer, M. (2018) · Thrombosis and Haemostasis · doi:10.1160/th17-10-0733 · Cited by 90
Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study
Piran, S., Traquair, H., Chan, N., Bhagirath, V. C., & Schulman, S. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12146 · Cited by 89
Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation
Arbel, R., Sergienko, R., Hammerman, A., Greenberg‐Dotan, S., Batat, E., Avnery, O. H., & Ellis, M. H. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.01.025 · Cited by 88
Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study
Rutherford, O.-C. W., Jonasson, C., Ghanima, W., Söderdahl, F., & Halvorsen, S. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz086 · Cited by 92
2020 Clinical practice guidelines for Chronic heart failure
Russian Society of Cardiology (2020) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2020-4083 · Cited by 88
Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF
Harrington, J., Carnicelli, A., Hua, K., Wallentin, L. C., Patel, M. R., Hohnloser, S. H., Giugliano, R. P., Fox, K. A. A., Hijazi, Z., Lópes, R. D., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062752 · Cited by 92
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation
Doshi, S. K., Kar, S., Nair, D. G., Waggoner, T. E., Agarwal, H., Moussavian, M., کاشانی, ا., Oza, S. R., Feldman, L. A., Sadhu, A. K., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2517213 · Cited by 88
New Oral Anticoagulants
Poulsen, B. K., Grove, E. L., & Husted, S. (2012) · Drugs · doi:10.2165/11635730-000000000-00000 · Cited by 87
Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
Lip, G. Y. H., Kongnakorn, T., Phatak, H. M., Kuznik, A., Lanitis, T., Liu, L. Z., Iloeje, U. H., Hernandez, L. G., & Dorian, P. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.12.011 · Cited by 88
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups
Lip, G. Y. H., Mitchell, S., Liu, X., Liu, L. Z., Phatak, H. M., Kachroo, S., & Batson, S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.11.084 · Cited by 90
Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study
Kuwahara, T., Abe, M., Yamaki, M., Fujieda, H., Abe, Y., HASHIMOTO, K., ISHIBA, M., Sakai, H., Hishikari, K., Takigawa, M., et al. (2016) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.12928 · Cited by 87
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study
Testa, S., Legnani, C., Tripodi, A., Paoletti, O., Pengo, V., Abbate, R., Bassi, L., Carraro, P., Cini, M., Paniccia, R., et al. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13486 · Cited by 87
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial
Lópes, R. D., Vora, A. N., Liaw, D., Granger, C. B., Darius, H., Goodman, S. G., Mehran, R., Windecker, S., & Alexander, J. H. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.03.001 · Cited by 89
Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation
Yu, H. T., Yang, P., Jang, E., Kim, T., Uhm, J., Kim, J., Pak, H., Lee, M., Lip, G. Y. H., & Joung, B. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014177 · Cited by 90
Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population‐based cohort study
Ording, A. G., Horváth–Puhó, E., Adelborg, K., Pedersen, L. H., Prandoni, P., & Sørensen, H. T. (2017) · Cancer Medicine · doi:10.1002/cam4.1054 · Cited by 87
Left Atrial Appendage Occlusion
Holmes, D. R., Lakkireddy, D., Whitlock, R. P., Waksman, R., & Mack, M. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.08.1631 · Cited by 88
Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment
Diener, H., Foerch, C., Riess, H. B., Röther, J., Schroth, G., & Weber, R. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70101-7 · Cited by 84
Meta-Analysis of Randomized Controlled Trials on Risk of Myocardial Infarction from the Use of Oral Direct Thrombin Inhibitors
Artang, R., Rome, E., Nielsen, J. D., & Vidaillet, H. J., Jr. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.027 · Cited by 90
Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial
Pol, T., Held, C., Westerbergh, J., Lindbäck, J., Alexander, J. H., Alings, M., Erol, Ç., Goto, S., Halvorsen, S., Huber, K., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007444 · Cited by 89
Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants
Shahjouei, S., Tsivgoulis, G. K., Goyal, N., Sadighi, A., Mowla, A., Wang, M., Seiffge, D. J., & Zand, R. (2019) · Stroke · doi:10.1161/strokeaha.119.026426 · Cited by 92
Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice
Roberti, R., Iannone, L. F., Palleria, C., Curcio, A., Rossi, M., Sciacqua, A., Armentaro, G., Vero, A., Manti, A., Cassano, V., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.684638 · Cited by 92
Evaluation of Cold Plasma Treatment and Safety in Disinfecting 3-week Root Canal Enterococcus faecalis Biofilm In Vitro
Li, Y., Sun, K., Ye, G., Liang, Y., Pan, H., Wang, G., Zhao, Y., Pan, J., Zhang, J., & Fang, J. (2015) · Journal of Endodontics · doi:10.1016/j.joen.2014.10.020 · Cited by 91
Atrial fibrillation in women: treatment
Ko, D., Rahman, F., Martins, M. A. P., Hylek, E. M., Ellinor, P. T., Schnabel, R. B., Benjamin, E. J., & Christophersen, I. E. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.171 · Cited by 87
Rivaroxaban vs Warfarin Sodium in the Ultra-Early Period After Atrial Fibrillation–Related Mild Ischemic Stroke
Hong, K., Kwon, S. U., Lee, S. H., Lee, J. S., Kim, Y., Song, T., Kim, Y. D., Park, M., Kim, E. G., Cha, J., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2161 · Cited by 89
Clinical and Radiographic Predictors of Intracerebral Hemorrhage Outcome
Al‐Mufti, F., Thabet, A. M., Singh, T., El-Ghanem, M. H., Amuluru, K., & Gandhi, C. D. (2018) · Interventional Neurology · doi:10.1159/000484571 · Cited by 84
Antithrombotic Therapy After Transcatheter Aortic Valve Replacement
Guedeney, P., Mehran, R., Collet, J., Claessen, B. E. P. M., ten Berg, J. M., & Dangas, G. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.118.007411 · Cited by 87
Efficacy of Direct Acting Oral Anticoagulants in Treatment of Left Ventricular Thrombus
Fleddermann, A. M., Hayes, C. H., Magalski, A., & Main, M. L. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.05.009 · Cited by 87
Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
Grymonprez, M., Steurbaut, S., de Backer, T. L., Petrović, M., & Lahousse, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.583311 · Cited by 84
Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: A randomized clinical trial
Shim, C. Y., Seo, J., Kim, Y. J., Lee, S. H., Caterina, R. D., Lee, S. H., Hong, G.-R., Shin, D., Seo, J., Lee, C. J., et al. (2021) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2021.01.127 · Cited by 87
A Prospective Study of Estimated Glomerular Filtration Rate and Outcomes in Patients With Atrial Fibrillation
Banerjee, A., Fauchier, L., Vourc’h, P., Andres, C. R., Taillandier, S., Halimi, J., & Lip, G. Y. H. (2013) · CHEST Journal · doi:10.1378/chest.13-2103 · Cited by 87
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score
Smith, J. G., Wieloch, M., Koul, S. M., Braun, O. Ö., Lumsden, J., Rydell, E., Öhman, J. N., Scherstén, F., Svensson, P. J., & van der Pals, J. (2012) · EuroIntervention · doi:10.4244/eijv8i6a105 · Cited by 85
New oral anticoagulants and regional anaesthesia
Benzon, H. T., Avram, M. J., Green, D., & Bonow, R. O. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet401 · Cited by 87

Authors: Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., Bahit, M. C., Diaz, R., Easton, J. D., Ezekowitz, J. A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B. J., Golitsyn, S., Goto, S., Hermosillo, A. G., Hohnloser, S. H., Horowitz, J., Mohan, P., Jansky, P., Lewis, B. S., Lopez-Sendon, J. L., Pais, P., Parkhomenko, A., Verheugt, F. W. A., Zhu, J., & Wallentin, L.
Affiliations: Duke Medical Center (US)
Boston University (US)
Bristol-Myers Squibb (United States) (US)
Lenox Hill Hospital (US)
Oslo University Hospital (NO)
Estudios Clínicos Latinoamérica (AR)
University of California, San Francisco (US)
University of Alberta (CA)
University of Missouri Health System (US)
University of New Mexico (US)
Mayo Clinic (US)
Tokai University (JP)
Instituto Nacional de Cardiología (MX)
Goethe University Frankfurt (DE)
The University of Adelaide (AU)
Carmel Medical Center (IL)
Hospital Universitario La Paz (ES)
St.John's Medical College Hospital (IN)
OLVG (NL)
Fu Wai Hospital (CN)
Uppsala University (SE)
ORCID: Granger, Christopher B.
Alexander, John H.
McMurray, John J.V.
Hylek, Elaine M.
Ansell, Jack
Atar, Dan
Bahit, M. Cecilia
Easton, J. Donald
Ezekowitz, Justin A.
Garcia, David
Gersh, Bernard J.
Goto, Shinya
Hohnloser, Stefan H.
Horowitz, John
Lewis, Basil S.
Lopez-Sendon, Jose Luis
Parkhomenko, Alexander
Verheugt, Freek W.A.
Zhu, Jun
Wallentin, Lars
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2011-09-15
Volume: 365
Issue: 11
Pages: 981-992
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1107039
OpenAlex: W2162508946
Cited by: 8,943
References: 15
Citations by year: 2026: 274 · 2025: 391 · 2024: 464 · 2023: 518 · 2022: 545 · 2021: 663 · 2020: 695 · 2019: 619 · 2018: 696 · 2017: 679 · 2016: 726 · 2015: 696 · 2014: 659 · 2013: 687 · 2012: 523
FWCI: 430.89
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Research Bank (Australian Catholic University) (submittedVersion)
Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
Funders: Japan Society for the Promotion of Science (21390244, 21590911)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
Keywords: apixaban, warfarin, atrial fibrillation, direct factor Xa inhibitors, oral anticoagulation, stroke prevention, systemic embolism, hemorrhagic stroke, ischemic stroke, major bleeding, non-inferiority, vitamin K antagonists, mortality, risk stratification, CHA2DS2-2V2 score, bleeding risk score
MeSH terms: Aged, Anticoagulants, Atrial Fibrillation, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Thromboembolism, Warfarin, Treatment Outcome, International Normalized Ratio, Stroke, Kaplan-Meier Estimate, Factor Xa Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Apixaban versus Warfarin in Patients with Atrial Fibrillation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks